What are the criteria for classifying asthma as mild, moderate, and severe—including symptom frequency, nighttime awakenings, activity limitation, and FEV1 percentage predicted—and what are the recommended treatment regimens for each classification?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Asthma Classification: Mild, Moderate, and Severe

Asthma severity is classified into four categories—intermittent, persistent-mild, persistent-moderate, and persistent-severe—based on two domains: impairment (symptom frequency, nighttime awakenings, rescue inhaler use, activity limitation, and FEV1) and risk (exacerbation frequency requiring oral corticosteroids). 1, 2

Classification Criteria for Patients ≥12 Years

Intermittent Asthma

  • Symptoms: ≤2 days per week
  • Nighttime awakenings: ≤2 times per month
  • Short-acting beta-agonist use: ≤2 days per week
  • Activity limitation: None
  • FEV1: ≥80% predicted; FEV1/FVC normal
  • Exacerbations requiring oral corticosteroids: 0-1 per year 1, 2

Persistent-Mild Asthma

  • Symptoms: >2 days per week but not daily
  • Nighttime awakenings: 3-4 times per month
  • Short-acting beta-agonist use: >2 days per week but not daily, and not more than once per day
  • Activity limitation: Minor limitation
  • FEV1: ≥80% predicted; FEV1/FVC reduced >5%
  • Exacerbations requiring oral corticosteroids: ≥2 per year 1, 2

Persistent-Moderate Asthma

  • Symptoms: Daily
  • Nighttime awakenings: >Once per week but not nightly
  • Short-acting beta-agonist use: Daily
  • Activity limitation: Some limitation
  • FEV1: >60% but <80% predicted; FEV1/FVC reduced >5%
  • Exacerbations requiring oral corticosteroids: ≥2 per year 1, 2

Persistent-Severe Asthma

  • Symptoms: Throughout the day
  • Nighttime awakenings: Often 7 times per week
  • Short-acting beta-agonist use: Several times per day
  • Activity limitation: Extremely limited
  • FEV1: <60% predicted; FEV1/FVC reduced
  • Exacerbations requiring oral corticosteroids: ≥2 per year 1, 2

Critical Classification Principles

Assign severity to the most severe category in which ANY feature occurs—this is the key rule that prevents underestimating disease severity. 1, 2 For example, if a patient has symptoms only twice weekly but FEV1 is 65% predicted, they are classified as persistent-moderate, not intermittent.

Patients with ≥2 exacerbations requiring oral corticosteroids in the past year are considered to have persistent asthma, even if all other impairment categories suggest intermittent disease. 2 This recognizes that exacerbation risk is independent of day-to-day symptoms.

Age-Specific FEV1/FVC Normal Values

  • Ages 8-19 years: 85%
  • Ages 20-39 years: 80%
  • Ages 40-59 years: 75%
  • Ages 60-80 years: 70% 1

Treatment Recommendations by Severity

Step 1 (Intermittent):

As-needed low-dose ICS-formoterol is now preferred over SABA monotherapy, as it significantly reduces moderate-to-severe exacerbations. 3

Step 2 (Persistent-Mild):

As-needed low-dose ICS-formoterol remains the recommended approach. 3

Step 3 (Persistent-Moderate):

Low-dose ICS-LABA maintenance therapy. ICS-LABA combinations demonstrate synergistic anti-inflammatory effects equivalent to or better than doubling the ICS dose, with improved adherence and reduced high-dose ICS adverse effects. 3

Step 4 (Persistent-Moderate to Severe):

Medium- to high-dose ICS-LABA. Consider adding leukotriene receptor antagonists if control remains suboptimal.

Step 5 (Persistent-Severe):

High-dose ICS-LABA plus additional controller (LAMA, biologics, or low-dose oral corticosteroids ≤7.5 mg/day prednisone equivalent as last resort). 3

Important Clinical Caveats

Classification is for initiating therapy in treatment-naïve patients. 1 Once treatment begins, shift focus from "severity" to "control" assessment—well-controlled versus not well-controlled—to guide step-up or step-down decisions. 4

Severity can change over time and is most readily recognized through ongoing care. 1 A patient initially classified as mild may progress to moderate or severe, necessitating regular reassessment every 2-4 weeks initially, then every 1-3 months once stable. 3

Both physicians and patients consistently underestimate asthma severity and overestimate control. 2 In surveys, 39-70% of patients with moderate symptoms reported their asthma as "well controlled." 2 This underscores the need for objective spirometry measurements, not just symptom assessment.

The term "mild-intermittent" has been eliminated from current classifications because it only applies to truly mild disease and fails to capture patients with intermittent but severe exacerbations. 1

References

3
Research

[Guidelines for the prevention and management of bronchial asthma (2024 edition)].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2025

4
Guideline

attaining optimal asthma control: a practice parameter.

Journal of Allergy and Clinical Immunology, 2005

Related Questions

What is the appropriate treatment for a 30-year-old patient with bronchitis who smokes Black & Mild cigars and uses marijuana, presenting with a productive cough of brown and green sputum and requesting cough syrup?
In a 55-year-old man with a 20-year history of asthma now uncontrolled despite high-dose inhaled fluticasone‑salmeterol (Advair), tiotropium (Spiriva), and oral prednisone, with four exacerbations in the past year (one requiring hospitalization), marked eosinophilia (15% eosinophils, absolute count 1575), elevated total IgE (350 IU/mL), negative Aspergillus‑specific IgE, and normal nasal examination, which diagnostic test should be ordered next: stool ova‑and‑parasite studies, Aspergillus sputum culture, nasal endoscopy, or bronchoalveolar lavage?
What does the chest X‑ray showing a normal‑sized heart, mild bibasilar atelectasis or scarring, no infiltrate or pleural effusion, and thoracic spondylosis indicate for a 72‑year‑old female with recent viral cough and asthma exacerbation, and what should be communicated to her regarding her condition and management?
What is the appropriate management for a patient with bronchial asthma who has developed pneumonia?
What is the recommended stepwise management for a 10-year-old boy with nighttime cough, exertional dyspnea, scattered expiratory wheezes, nasal congestion, and atopic dermatitis that began after moving into a new rental home?
What is the most likely diagnosis for a 7‑month‑old infant presenting with fever followed by a facial rash?
In a patient with Crohn disease well controlled on pentasa (mesalamine) who experiences monthly self‑limited episodes of facial edema, erythema, and fever, what are the differential diagnoses?
What is the ideal mean arterial pressure (MAP) range for a myocardial infarction patient with an ejection fraction of 37% receiving norepinephrine infusion?
Is an albuterol metered-dose inhaler (MDI) the same as an albuterol nebulizer?
What is the appropriate workup for a patient presenting with weakness?
In a patient with recent acute myocardial infarction, ejection fraction 37 %, on norepinephrine infusion, and a high burden of premature ventricular complexes that degenerate into supraventricular tachycardia, is adenosine safe to give?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.